NCT00281008 - Study of ISIS 301012 (Mipomersen) in Heterozygous Familial Hypercholesterolemia Subjects on Lipid Lowering Therapy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2006

Primary Completion Date

July 31, 2007

Study Completion Date

December 31, 2007

Conditions

Hypercholesterolemia, Familial

Interventions

DRUG

ISIS 301012 or Placebo

50 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, and 36

DRUG

ISIS 301012 or Placebo

100 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, and 36

DRUG

ISIS 301012 or Placebo

200 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, and 36

DRUG

ISIS 301012 or Placebo

300 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, and 85

Trial Locations (8)

New York

Winston-Salem

Cincinnati

Chicago

Houston

Auburn

Scarborough

Amsterdam